Publications by authors named "S Gouerant"
This open-label, non-comparative, 2:1 randomized, phase II trial (NCT03275506) in women with stage IIIC/IV high-grade serous carcinoma (HGSC) for whom upfront complete resection was unachievable assessed whether adding pembrolizumab (200 mg every 3 weeks) to standard-of-care carboplatin plus paclitaxel yielded a complete resection rate (CRR) of at least 50%. Postoperatively patients continued assigned treatment for a maximum of 2 years. Postoperative bevacizumab was optional.
View Article and Find Full Text PDFArticle Synopsis
- The study compared two types of catheters (PICCs and PORTs) used for chemotherapy in breast cancer patients to see which is safer.
- It found that while both types had some problems, PICCs caused more issues and discomfort than PORTs.
- The research suggests that for treating breast cancer, PORTs are the better choice because they have fewer complications.
Article Synopsis
- The authors discovered that Table 2 in their original article was formatted incorrectly, leading to inaccuracies.
- They have released an updated version of Table 2 in a correction notice.
- The original article has also been revised to reflect these changes.
Background: New generation hormone-therapies (NGHT) targeting the androgen signalling pathway are nowadays proposed to elderly patients with metastatic castration-resistant prostate cancer (CRPCa). The impact of these treatments on cognitive function has never been evaluated whereas cognitive impairment may have an impact on the autonomy and the treatment adherence. The aim of this study is to prospectively assess the incidence of cognitive impairment in elderly men after treatment by NGHT for a metastatic CRPCa.
View Article and Find Full Text PDFPurpose: To assess the prognostic and predictive value of circulating ESR1 mutation and its kinetics before and after progression on aromatase inhibitor (AI) treatment.
Patients And Methods: ESR1 circulating D538G and Y537S/N/C mutations were retrospectively analyzed by digital droplet PCR after first-line AI failure in patients treated consecutively from 2010 to 2012 for hormone receptor-positive metastatic breast cancer. Progression-free survival (PFS) and overall survival (OS) were analyzed according to circulating mutational status and subsequent lines of treatment.